Dual-Drug Nanosystem: Etoposide Prodrug and Cisplatin Coloaded Nanostructured Lipid Carriers for Lung Cancer Therapy

References

• Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(4):504–535. doi:10.6004/jnccn.2017.0050
   PubMed Web of Science ®Google Scholar
• Mottaghitalab F, Farokhi M, Fatahi Y, Atyabi F, Dinarvand R. New insights into designing hybrid nanoparticles for lung cancer: diagnosis and treatment. J Control Release. 2019;295:250–267. doi:10.1016/j.jconrel.2019.01.009
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2016, Based on November 2018 SEER Data Submission, Posted to the SEER Web Site, April 2019. Bethesda, MD: National Cancer Institute; 2019.
   Google Scholar
• Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351–360.
   PubMed Web of Science ®Google Scholar
• Winton T, Livingston R, Johnson D, et al.; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352(25):2589–2597. doi:10.1056/NEJMoa043623
   PubMed Web of Science ®Google Scholar
• Senan S, Brade A, Wang LH, et al. PROCLAIM: randomized Phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34(9):953–962. doi:10.1200/JCO.2015.64.8824
   PubMed Web of Science ®Google Scholar
• Mymryk JS, Zaniewski E, Archer TK. Cisplatin inhibits chromatin remodeling, transcription factor binding, and transcription from the mouse mammary tumor virus promoter in vivo. Proc Natl Acad Sci U S A. 1995;92(6):2076–2080. doi:10.1073/pnas.92.6.2076
   PubMed Web of Science ®Google Scholar
• Khan MM, Madni A, Tahir N, et al. Co-Delivery of Curcumin and Cisplatin to Enhance Cytotoxicity of Cisplatin Using Lipid-Chitosan Hybrid Nanoparticles. Int J Nanomedicine. 2020;15:2207–2217. doi:10.2147/IJN.S247893
   PubMed Web of Science ®Google Scholar
• Zhu LJ, Gu LS, Shi TY, Zhang XY, Sun BW. Enhanced treatment effect of nanoparticles containing cisplatin and a GSH-reactive probe compound. Mater Sci Eng C Mater Biol Appl. 2019;96:635–641. doi:10.1016/j.msec.2018.11.039
   PubMed Web of Science ®Google Scholar
• Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 1998;34(10):1514–1521. doi:10.1016/S0959-8049(98)00228-7
   PubMed Web of Science ®Google Scholar
• Yordanov G, Skrobanska R, Evangelatov A. Colloidal formulations of etoposide based on poly(butyl cyanoacrylate) nanoparticles: preparation, physicochemical properties and cytotoxicity. Colloids Surf B Biointerfaces. 2013;101:215–222. doi:10.1016/j.colsurfb.2012.05.040
   PubMed Web of Science ®Google Scholar
• Jornada DH, Dos Santos Fernandes GF, Chiba DE, de Melo TR, Dos Santos JL, Chung MC. The prodrug approach: a successful tool for improving drug solubility. Molecules. 2015;21(1):42. doi:10.3390/molecules21010042
   PubMed Web of Science ®Google Scholar
• Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov. 2008;7(3):255–270. doi:10.1038/nrd2468
   PubMed Web of Science ®Google Scholar
• Schmidt F, Monneret C. Prodrug Mono Therapy: synthesis and biological evaluation of an etoposide glucuronide-prodrug. Bioorg Med Chem. 2003;11(10):2277–2283. doi:10.1016/S0968-0896(03)00108-1
   PubMed Web of Science ®Google Scholar
• Medical Advisory Secretariat. Nanotechnology: an evidence-based analysis. Ont Health Technol Assess Ser. 2006;6(19):1–43.
   Google Scholar
• De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3(2):133–149. doi:10.2147/IJN.S596
   PubMed Web of Science ®Google Scholar
• Chen G, Zhang Y, Deng H, Tang Z, Mao J, Wang L. Pursuing for the better lung cancer therapy effect: comparison of two different kinds of hyaluronic acid and nitroimidazole co-decorated nanomedicines. Biomed Pharmacother. 2020;125:109988. doi:10.1016/j.biopha.2020.109988
   PubMed Web of Science ®Google Scholar
• Cao C, Wang Q, Liu Y. Lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers. Drug Des Devel Ther. 2019;13:1087–1098. doi:10.2147/DDDT.S198003
   PubMed Web of Science ®Google Scholar
• Guo S, Zhang Y, Wu Z, et al. Synergistic combination therapy of lung cancer: cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-Demethylnobiletin. Biomed Pharmacother. 2019;118:109225. doi:10.1016/j.biopha.2019.109225
   PubMed Web of Science ®Google Scholar
• Rawal S, Patel B, Patel MM. Fabrication, optimisation and in vitro evaluation of docetaxel and curcumin Co-loaded nanostructured lipid carriers for improved antitumor activity against non-small cell lung carcinoma. J Microencapsul. 2020;37(8):543–556. doi:10.1080/02652048.2020.1823498
   PubMed Web of Science ®Google Scholar
• Shabat D, Lode HN, Pertl U, et al. In vivo activity in a catalytic antibody-prodrug system: antibody catalyzed etoposide prodrug activation for selective chemotherapy. Proc Natl Acad Sci U S A. 2001;98(13):7528–7533. doi:10.1073/pnas.131187998
   PubMed Web of Science ®Google Scholar
• Zhang K, Lv S, Li X, et al. Preparation, characterization, and in vivo pharmacokinetics of nanostructured lipid carriers loaded with oleanolic acid and gentiopicrin. Int J Nanomedicine. 2013;8:3227–3239. doi:10.2147/IJN.S45031
   PubMed Web of Science ®Google Scholar
• Hong Y, Che S, Hui B, et al. Lung cancer therapy using doxorubicin and curcumin combination: targeted prodrug based, pH sensitive nanomedicine. Biomed Pharmacother. 2019;112:108614. doi:10.1016/j.biopha.2019.108614
   PubMed Web of Science ®Google Scholar
• Zhu R, Wang Q, Zhu Y, et al. pH sensitive nano layered double hydroxides reduce the hematotoxicity and enhance the anticancer efficacy of etoposide on non-small cell lung cancer. Acta Biomater. 2016;29:320–332. doi:10.1016/j.actbio.2015.10.029
   PubMed Web of Science ®Google Scholar
• Song Z, Shi Y, Han Q, Dai G. Endothelial growth factor receptor-targeted and reactive oxygen species-responsive lung cancer therapy by docetaxel and resveratrol encapsulated lipid-polymer hybrid nanoparticles. Biomed Pharmacother. 2018;105:18–26. doi:10.1016/j.biopha.2018.05.095
   PubMed Web of Science ®Google Scholar
• Xu G, Chen Y, Shan R, Wu X, Chen L. Transferrin and tocopheryl-polyethylene glycol-succinate dual ligands decorated, cisplatin loaded nano-sized system for the treatment of lung cancer. Biomed Pharmacother. 2018;99:354–362. doi:10.1016/j.biopha.2018.01.062
   PubMed Web of Science ®Google Scholar
• Zheng G, Zheng M, Yang B, Fu H, Li Y. Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo. Biomed Pharmacother. 2019;116:109006. doi:10.1016/j.biopha.2019.109006
   PubMed Web of Science ®Google Scholar
• Wang G, Wang Z, Li C, et al. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy. Biomed Pharmacother. 2018;106:275–284. doi:10.1016/j.biopha.2018.06.137
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621e81. doi:10.1124/pr.58.3.10
   Web of Science ®Google Scholar
• Cai L, Xu G, Shi C, Guo D, Wang X, Luo J. Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: a synergistic combination nanotherapy for ovarian cancer treatment. Biomaterials. 2015;37:456–468. doi:10.1016/j.biomaterials.2014.10.044
   PubMed Web of Science ®Google Scholar
• Baharara J, Ramezani T, Divsalar A, Mousavi M, Seyedarabi A. Induction of apoptosis by green synthesized gold nanoparticles through activation of caspase-3 and 9 in human cervical cancer cells. Avicenna J Med Biotechnol. 2016;8(2):75–83.
   PubMedGoogle Scholar
• Wang P, Wang H, Huang Q, et al. Exosomes from M1-polarized macrophages enhance paclitaxel antitumor activity by activating macrophages-mediated inflammation. Theranostics. 2019;9(6):1714–1727. doi:10.7150/thno.30716
   PubMed Web of Science ®Google Scholar
• Thomas AM, Kapanen AI, Hare JI, et al. Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy. J Control Release. 2011;150(2):212–219. doi:10.1016/j.jconrel.2010.11.018
   PubMed Web of Science ®Google Scholar
• Sun G, Sun K, Sun J. Combination prostate cancer therapy: prostate-specific membranes antigen targeted, pH-sensitive nanoparticles loaded with doxorubicin and tanshinone. Drug Deliv. 2021;28(1):1132–1140. doi:10.1080/10717544.2021.1931559
   PubMed Web of Science ®Google Scholar
• Shao Y, Luo W, Guo Q, Li X, Zhang Q, Li J. In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy. Drug Des Devel Ther. 2019;13:2043–2055. doi:10.2147/DDDT.S202818
   PubMed Web of Science ®Google Scholar
• Hong Y, Che S, Hui B, Wang X, Zhang X, Ma H. Combination therapy of lung cancer using layer-by-layer cisplatin prodrug and curcumin co-encapsulated nanomedicine. Drug Des Devel Ther. 2020;14:2263–2274. doi:10.2147/DDDT.S241291
   PubMed Web of Science ®Google Scholar
• Jiang H, Geng D, Liu H, Li Z, Cao J. Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors. Drug Deliv. 2016;23(9):3665–3673. doi:10.1080/10717544.2016.1217954
   PubMed Web of Science ®Google Scholar
• Wang J. Combination treatment of cervical cancer using folate-decorated, pH-sensitive, carboplatin and paclitaxel co-loaded lipid-polymer hybrid nanoparticles. Drug Des Devel Ther. 2020;14:823–832. doi:10.2147/DDDT.S235098
   PubMed Web of Science ®Google Scholar
• Macedo LB, Nogueira-Librelotto DR, de Vargas J, Scheeren LE, Vinardell MP, Rolim CMB. Poly (ɛ-Caprolactone) nanoparticles with pH-responsive behavior improved the in vitro antitumor activity of methotrexate. AAPS Pharm Sci Tech. 2019;20(5):165. doi:10.1208/s12249-019-1372-5
   PubMed Web of Science ®Google Scholar
• Luan J, Zhang D, Hao L, et al. Preparation, characterization and pharmacokinetics of Amoitone B-loaded long circulating nanostructured lipid carriers. Colloids Surf B Biointerfaces. 2014;114:255–260. doi:10.1016/j.colsurfb.2013.10.018
   PubMed Web of Science ®Google Scholar
• Mao K, Zhang W, Yu L, Yu Y, Liu H, Zhang X. Transferrin-decorated protein-lipid hybrid nanoparticle efficiently delivers cisplatin and docetaxel for targeted lung cancer treatment. Drug Des Devel Ther. 2021;15:3475–3486. doi:10.2147/DDDT.S296253
   PubMed Web of Science ®Google Scholar
• Chen W, Guo M, Wang S. Anti prostate cancer using PEGylated bombesin containing, cabazitaxel loading nano-sized drug delivery system. Drug Dev Ind Pharm. 2016;42(12):1968–1976. doi:10.1080/03639045.2016.1185438
   PubMed Web of Science ®Google Scholar
• Bao H, Zheng N, Li Z, Zhi Y. Synergistic effect of tangeretin and atorvastatin for colon cancer combination therapy: targeted delivery of these dual drugs using RGD peptide decorated nanocarriers. Drug Des Devel Ther. 2020;14:3057–3068. doi:10.2147/DDDT.S256636
   PubMed Web of Science ®Google Scholar
• Liang Z, Li J, Zhu B. Lung cancer combination treatment: evaluation of the synergistic effect of cisplatin prodrug, vinorelbine and retinoic acid when co-encapsulated in a multi-layered nano-platform. Drug Des Devel Ther. 2020;14:4519–4531. doi:10.2147/DDDT.S251749
   PubMed Web of Science ®Google Scholar
• Tan S, Wang G. Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo. Drug Des Devel Ther. 2017;11:3519–3529. doi:10.2147/DDDT.S151422
   PubMed Web of Science ®Google Scholar
• Wang B, Hu W, Yan H, et al. Lung cancer chemotherapy using nanoparticles: enhanced target ability of redox-responsive and pH-sensitive cisplatin prodrug and paclitaxel. Biomed Pharmacother. 2021;136:111249. doi:10.1016/j.biopha.2021.111249
   PubMed Web of Science ®Google Scholar
• Zhang J, Xiao X, Zhu J, et al. Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy. Int J Nanomedicine. 2018;13:3039–3051. doi:10.2147/IJN.S161163
   PubMed Web of Science ®Google Scholar